|Articles|October 9, 2008

German Study Supports St. John's Wort Depression Claim

The plant extract of Hypericum perforatum, or St. John’s wort, is grown on nearly every continent in the world, but has only recently been scientifically cited as a potential gatekeeper for depression. The study, reported in the Cochrane Systematic Review (United Kingdom) in October, included reviews of 29 trials with a total of 5,489 patients prescribed with symptoms of “major depression.”

The plant extract of Hypericum perforatum, or St. John’s wort, is grown on nearly every continent in the world, but has only recently been scientifically cited as a potential gatekeeper for depression. The study, reported in the Cochrane Systematic Review (United Kingdom) in October, included reviews of 29 trials with a total of 5,489 patients prescribed with symptoms of “major depression.”

"Overall, we found that the St. John's wort extracts tested in the trials were superior to placebos and as effective as standard antidepressants, with fewer side effects," said lead researcher, Klaus Linde of the Centre for Complementary Medicine in Munich, Germany.

While researchers applauded the effects of St. John’s wort in depression patients, they were quick to note that the plant should not be labeled as an anti-depressant, especially since the effects of its fusion with other drugs is not yet known.

"Using a St. Johns wort extract might be justified, but products on the market vary considerably, so these results only apply to the preparations tested," said Linde.

The report comes in light of a 2002 NCCAM (Bethesda, Maryland) sponsored study that showed that “the herb was no more effective than placebo in treating major depression of moderate severity.”

"Overall, we found that patients taking either St. John's wort or placebo had similar rates of response according to scales commonly used for measuring depression," concluded the 2002 NCCAM report.

The new Cochrane report noted that results were more favorable in German-speaking countries where doctors regularly prescribe St. John’s wort as an herbal treatment.


Related to this article

SupplySide Global Vitaquest
Live from SupplySide Global 2026, Nutritional Outlook’s Nicholas Jacobus speaks with Michael Anthonavage, VP of innovation at Vitaquest International, about the company’s 2027 consumer trends forecast and how it’s shaping supplement formulation.
Laurentia Bliss
Live from SupplySide Global 2026, Laurentia Bliss talks about new athlete-focused research on Magtein, ThreoTech’s brain-targeted magnesium ingredient, and upcoming innovations like effervescent tablets and gummies.
Klaus Neumann
Live from SupplySide Global 2026, Klaus Neumann talks about Concordix's chewable supplement line spanning beauty and gut-immune health, including BeautyBioti, a Skin & Hair Vitality Complex, and FortiBiotic.